

# Morphotek, Inc Product Pipeline Review 2016

*'Morphotek, Inc. - Product Pipeline Review - 2016', provides an overview of the Morphotek, Inc.'s pharmaceutical research and development focus.*

PUNE, INDIA, April 14, 2016 /EINPresswire.com/ -- The report "[Morphotek, Inc. - Product Pipeline Review - 2016](#)" provides comprehensive information on the therapeutics under development by Morphotek, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Access a Report Copy @ <https://www.wiseguyreports.com/reports/morphotek-inc-product-pipeline-review-2016> .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note\*: Certain sections in the report may be removed or altered based on the availability and



relevance of data.

## Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Morphotek, Inc.
- The report provides overview of Morphotek, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Morphotek, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Morphotek, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Purchase a 1-User License Copy @

[https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=393575](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=393575) .

## Reasons to buy

- Evaluate Morphotek, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Morphotek, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Morphotek, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Major Point in Table of Content

Morphotek, Inc. - Drug Profiles 14

amatuximab 14

Product Description 14

Mechanism of Action 14  
R&D Progress 14  
farletuzumab 17  
Product Description 17  
Mechanism of Action 17  
R&D Progress 17  
ontuxizumab 20  
Product Description 20  
Mechanism of Action 20  
R&D Progress 20  
KANAb-071 22  
Product Description 22  
Mechanism of Action 22  
R&D Progress 22  
MORAb-022 23  
Product Description 23  
Mechanism of Action 23  
R&D Progress 23  
MORAb-066 24  
Product Description 24  
Mechanism of Action 24  
R&D Progress 24  
Monoclonal Antibody Conjugates for Oncology 25  
Product Description 25  
Mechanism of Action 25  
R&D Progress 25  
MORAb-047 26  
Product Description 26  
Mechanism of Action 26  
R&D Progress 26  
MORAb-048 27  
Product Description 27  
Mechanism of Action 27  
R&D Progress 27  
MORAb-050 28  
Product Description 28  
Mechanism of Action 28  
R&D Progress 28  
MORAb-075 29  
Product Description 29  
Mechanism of Action 29  
R&D Progress 29

Inquire for more information @ <https://www.wiseguyreports.com/enquiry/morphotek-inc-product-pipeline-review-2016> .

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

16468459349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/321381721>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.